ASML Holding N.V. (NASDAQ: ASML) was raised to Buy from Neutral at UBS. The price target was raised to €130 from €118 (versus €116.80 in overseas trading). ASML closed at $121.25 in New York trading on Thursday and were indicated up about 2% at $123.63 on Friday. The American depositary shares have a consensus price target of $117.13 and a 52-week range of $98.71 to $127.60.
Camden Property Trust (NYSE: CPT) was raised to Buy from Neutral and the price target was raised to $94 from $84 at Goldman Sachs.
Cara Therapeutics Inc. (NASDAQ: CARA) was reiterated as Buy, but the fair value target was raised to $20 from $18 (versus a $17.49 close), at Janney. The call was based on four clinical catalysts in four months.
EnLink Midstream LLC (NYSE: ENLC) was started as Neutral with a $21 fair value target (versus a $19.50 close) at Janney. As below, they feel the positives are mostly priced into the units now.
EnLink Midstream Partners L.P. (NYSE: ENLK) was started as Neutral with a $20 fair value target (versus an $18.60 close) at Janney. While the firm noted that EnLink Partners has the best-in-class exposure to robust long-term volume growth in the STACK, it feels that the unit price mostly reflects this outlook.
Enova International Inc. (NYSE: ENVA) was raised to Buy from Neutral and the fair value target was raised to $16 from $13 at Janney. The firm’s overriding concern on Enova had been the sustainability of the company’s profitability when the CFPB’s payday loan installment rules go into effect, but they now are more convinced that this proposed rule-set will never actually make its way into an active law.
FMSA Holdings Inc. (NYSE: FMSA) was raised to Buy from Hold, but the price target was lowered to $10 from $12 (versus a $7.30 close), at Jefferies. The firm is comfortable with supply and demand issues in fracking sand, but the noted tempering price assumptions and slow raw frac volume growth in 2018 to 2020.
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) was downgraded to Sell from Neutral and the price target was cut to $25 from $28 (versus a $45.80 close) at Goldman Sachs.
MEDNAX Inc. (NYSE: MD) was downgraded to Neutral from Overweight at JPMorgan.
NextEra Energy Partners L.P. (NYSE: NEP) was reiterated as Outperform and the price target was raised to $40 from $30 (versus a $30.59 close) at Credit Suisse. The firm believes that there is room to run higher with catalysts ahead. NextEra Energy Partners has a 52-week range of $23.90 to $32.95 and a consensus price target of $34.94.
Thursday’s top analyst upgrades and downgrades included American Express, Amgen, Encana, Gilead Sciences, Tesla and over a dozen more.